In recent years, some clinical trials about medication therapy for patients with CKD and HFpEF have occurred, including the “golden Triangle” medication which is recognized for the treatment of HFrEF: β-blockers, renin–angiotensin system (RAS) inhibitors, aldosterone receptor antagonist, as well as the research hotspot—sacubitril–valsartan (ARNI) and so on. Here, REN is linked to chronic kidney disease.